BioDelivery Sciences International (NSDQ:BDSI) said today that Health Canada approved its buprenorphine hydrochloride buccal film, Belbuca, for the management of pain severe enough to necessitate daily, long-term opioid treatment and for which alternative management options are inadequate.
The company said it plans to commercialize Belbuca in Canada through an unnamed partner and that the launch is set for early 2018.
Get the full story at our sister site, Drug Delivery Business News.
